Cara Therapeutics (CARA) Reports In-Line Q3 EPS

Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.52), in-line with the analyst estimate of ($0.52). Revenue for the quarter came in at $4.87 million versus the consensus estimate of $9.95 million.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance
• Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance